Announcements Trials
Browse Landscape

Phase

Phase 1 13Phase 2 8Phase 1/2 4Phase NA 1Phase EARLY_PHASE1 1Phase 3 1

Status

Terminated 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1Gastrointestinal 1Dermatologic 1

Conditions

Uveal Melanoma 1Stomach Neoplasms 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Melanoma 1Leukemia, Myeloid 1Leukemia, Lymphoid 1Leukemia, B-Cell 1Leukemia 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 35Carboplatin 24Specimen Handling 20Cyclophosphamide 18Magnetic Resonance Spectroscopy 17fludarabine 15Nivolumab 14Dexamethasone 14Bevacizumab 14Gemcitabine 12Biopsy 12atezolizumab 11Temozolomide 11Paclitaxel 10venetoclax 9Pemetrexed 9Ipilimumab 9Docetaxel 9Cisplatin 9Rituximab 8Lenalidomide 8blinatumomab 7Prednisone 7Oxaliplatin 7Fluorouracil 7Capecitabine 7olaparib 6lenvatinib 6Vincristine 6Radiotherapy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × fludarabine phosphate × 30 days × Clear all
NCT07627698 2026-06-04

DUET-MEL

Beijing Biotech

Phase 1/2 Recruiting
36 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT07604233 2026-06-01

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
30 enrolled
Other hematologic neoplasm

Leukemia, Myeloid

NCT03573700 2026-05-20

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

St. Jude Children's Research Hospital

Phase 1/2 Active not recruiting
24 enrolled 9 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphoid, Recurrence, Leukemia, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03745326 2026-05-19

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
5 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡